Pirbright joins a consortium of six institutes to receive funding of £1.6 million to support collaborative research against infectious diseases.
The consortium, which sees world-leading experts from Pirbright, the Liverpool School of Tropical Medicine, UK Health Security Agency, London School of Hygiene & Tropical Medicine, University of Oxford and the Science and Technology Facilities Council (STFC) laboratories come together, has received funding from the UK Research and Innovation Medical Research Council (UKRI MRC) through their Impact Acceleration Account (IAA) scheme.
Their aim is to enhance research and promote collaboration to develop diagnostic tests, vaccines, and treatments for economically important infectious diseases of humans and animals.
Funding will support both early career researchers and more senior scientists to shape their research to have real-world impact.
The consortium will also encourage cross-sector collaboration by engaging with industrial partners and promote the sharing of expertise across the six partner institutes. This is essential to enable knowledge exchange, ensuring that global health issues are tackled effectively.
Professor Bryan Charleston, Director of The Pirbright Institute and Head of the Viral Immunology group said: “This is an excellent opportunity to collaborate with other leading experts in all aspects of infectious disease. This funding will allow the expertise at Pirbright to be shared across the UK to achieve a common goal – to improve diagnosis, treatment and prevention of infectious diseases that have significant detrimental impacts on human and animal health”.